Tenderwize
Retour à la recherche

Open-house rebate agreement for Pamidronic acid

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jan 31, 2028 · 521 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Pamidronsäure (ATC-Code nach WHO: M05BA03)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

The open-house procedure may be terminated early if exclusive rebate agreements are concluded, which could shorten the...

Demand and purchase volume are unknown, and minimum purchase quantities are not guaranteed.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jan 2028
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Pamidronic acid (ATC M05BA03).
  • Open-house participation model allowing eligible pharmaceutical companies to join during the participation period.
Afficher le résumé complet

This is an open-house supply arrangement for non-exclusive pharmaceutical rebate agreements for Pamidronic acid (ATC M05BA03) with AOK PLUS. The notice states that any interested pharmaceutical company meeting the participation conditions may join during the participation period, with no individual negotiations and no exclusivity. Documents are available via DTVP, but no procurement document text was provided for analysis, so several submission details remain document-dependent and incomplete.

Risques

The open-house procedure may be terminated early if exclusive rebate agreements are concluded, which could shorten the...

Demand and purchase volume are unknown, and minimum purchase quantities are not guaranteed.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicines.
  • The company must accept the participation conditions and the rebate agreement terms.

Eligibility

  • Submission of the completed declaration on the absence of exclusion grounds (Eigenerklärung zum Nichtvorliegen von Ausschlussgründen).

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreement for Pamidronic acid

Single lot for concluding non-exclusive pharmaceutical rebate agreements for medicines containing Pamidronic acid (ATC M05BA03). The lot is a supply arrangement under an open-house model; no exclusivity, no guaranteed minimum purchase volume, and the contract may be concluded with all interested eligible pharmaceutical companies during the participation period. Place of performance is Dresden, Germany, with broader reference to Saxony and Thuringia in the XML notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jan 2026 - Jan 2028

Catégorie

Pharmaceutical products

Date limite

Deadline Jan 31, 2028

Détails de la procédure

Date de publication
19 Oct 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
687423-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30